We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00199004
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : August 23, 2010
Sponsor:
Information provided by:

September 12, 2005
September 20, 2005
August 23, 2010
April 2004
March 2009   (Final data collection date for primary outcome measure)
Remission rate (cytologic, Remission rate (molecular), Remission duration, Disease free survival, Overall survival
  • - Remission rate (cytologic)
  • - Remission rate (molecular)
  • - Remission duration
  • - Disease free survival
  • - Overall survival
Complete list of historical versions of study NCT00199004 on ClinicalTrials.gov Archive Site
Dose and time compliance, Toxicity according to WHO, Death in induction and CR, Course of MRD
  • - Dose and time compliance
  • - Toxicity according to WHO
  • - Death in induction and CR
  • - Course of MRD
Not Provided
Not Provided
 
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients. Thereafter patients receive additional consolidation and reinduction cycles combined with rituximab. In parallel minimal residual disease is evaluated. After six months and one year the decision on intensification or discontinuation of therapy is made based on results of MRD evaluation
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Adult Acute Lymphocytic Leukemia
  • Drug: Cyclophosphamide
  • Drug: Dexamethasone / Prednisolone
  • Drug: Vincristine
  • Drug: Daunorubicin
  • Drug: Asparaginase
  • Drug: Methotrexate
  • Drug: Cytarabine
  • Drug: Mercaptopurine
  • Drug: G-CSF
  • Drug: Vindesine
  • Drug: VP16
  • Drug: Adriamycin
  • Drug: Thioguanine
  • Drug: VM26
  • Drug: Rituximab
  • Procedure: CNS irradiation
  • Procedure: Mediastinal irradiation (if residual TU)
  • Procedure: Stem cell transplantation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
March 2009
March 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • B-precursor ALL (common / pre B-ALL)
  • Standard risk
  • CD20 expression >20%
  • Ph/BCR-ABL negative
  • Age 15-65 years (55-65 if biologically younger)
  • Written informed consent

Exclusion Criteria:

  • Severe complications due to leukemia or secondary illnesses
  • Late relapse of childhood ALL
  • Cytostatic pretreatment
  • Pregnancy
  • Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent
  • Known severe allergy to foreign proteins
Sexes Eligible for Study: All
15 Years to 65 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00199004
GMALL03
Not Provided
Not Provided
Not Provided
Not Provided
Johann Wolfgang Goethe University Hospital
Not Provided
Study Chair: Dieter Hoelzer, MD,PhD University Hospital, Medical Dept. II
Johann Wolfgang Goethe University Hospital
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP